Science, shared openly

Scientific research at Formula Swiss

A closer look at our research collaborations and the published evidence. Start with the animal research library, or explore our wider scientific work below.

Roberto Chiocchetti
Professor Roberto Chiocchetti, University of Bologna

Our Bologna research, from project to publication

Follow the documented research programme and open the university record or original paper at each step.

  1. 2017–2018

    Earlier canine research

    The university records an Innovet-funded canine project in 2017–2018. Its published work provides background for the dog studies in this library.

    Read the original publication
  2. 2019–2021

    Formula Swiss funds a university project

    Professor Roberto Chiocchetti’s university record names Formula Swiss as funder of the 2019–2021 project on receptors in feline and equine digestive tissues and equine sensory ganglia.

    Read the university project record
  3. 2020

    Feline digestive research published

    The feline paper maps cannabinoid and related receptors in digestive tissues, contributing anatomical evidence for future research.

    Read the original publication
  4. 2020 / 2021

    Equine sensory research acknowledges our grant

    First published online in June 2020, this paper examined sensory tissue from six horses and explicitly acknowledged funding from Formula Swiss. It appeared in the journal’s 2021 volume.

    Read the original publication
  5. 2021

    Equine intestinal research published

    The horse ileum paper extends the university team’s receptor mapping to intestinal tissue. These publications investigate biology and do not test the effectiveness of the oils sold here.

    Read the original publication

Published CBD and cannabinoid research for animals

What the research tells us

The Bologna studies map cannabinoid receptors in animal tissues. They explain the biology, rather than test the effectiveness of the oils sold here.

Other teams have studied CBD absorption, tolerability and selected clinical outcomes. Results depend on the species, preparation and study design.

A laboratory report answers a different question: what was measured in the tested sample. Open the report for the product you are considering.

Animal research at the University of Bologna

Our collaboration with Professor Roberto Chiocchetti and his team supports a deeper understanding of the endocannabinoid system. These studies map receptors in animal tissues: an important foundation for further research.

2019–2021 · University of BolognaDocumented research support

Formula Swiss support is documented for the 2019–2021 cat and horse research project. The earlier canine studies shown here were funded by Innovet and form part of the same university team’s wider work.

Read the university project record

Receptor mapping explains where cannabinoids may act. It does not establish that a CBD product treats a condition, or determine a suitable dose.

Explore all relevant publications

Further published animal research

Explore studies from other research teams, including positive, mixed and null results. The preparations and conditions studied vary; these publications are not clinical trials of the Formula Swiss products offered here.

  • 2018Joint pain

    CBD oil and osteoarthritis in dogs: Gamble and colleagues

    Randomised placebo-controlled crossover trial

    Reported improvements in pain and activity measures during treatment with the tested CBD-rich oil.

    Study context and limitations

    Small, short trial of one specific extract; liver enzyme increases were observed. The results do not verify Formula Swiss products.

    Read the original publication
  • 2019Epilepsy

    CBD alongside conventional treatment for canine epilepsy

    Randomised blinded controlled trial

    Reported a median 33% reduction in seizure frequency in the CBD group; the proportion achieving at least a 50% reduction was similar between groups.

    Study context and limitations

    Small analysed sample, and CBD was given alongside existing treatment. Some dogs were withdrawn because of unsteadiness (ataxia), and liver enzyme increases were reported.

    Read the original publication
  • 2020Joint pain

    Daily cannabidiol for canine osteoarthritis pain

    Randomised double-blind placebo-controlled trial

    Reported improvements in pain and mobility with selected CBD doses and formulations.

    Study context and limitations

    Twenty dogs across treatment groups and four weeks of treatment; formulation and dose affected outcomes.

    Read the original publication
  • 2021Joint pain

    A placebo-controlled pilot study of CBD for canine osteoarthritis

    Randomised double-blind placebo-controlled crossover trial

    Found no differences between CBD and placebo in the recorded outcome measures.

    Study context and limitations

    Twenty-three dogs completed the trial. Liver enzyme increases and vomiting were reported.

    Read the original publication
  • 2023Stress

    Single-dose CBD during separation and car travel in dogs

    Blinded placebo-controlled parallel study

    Some behavioural and physiological stress measures improved with CBD compared with placebo.

    Study context and limitations

    Effects differed between measures and tests. A single dose in an experimental setting does not show that CBD treats anxiety disorders.

    Read the original publication
  • 2020Tolerability

    Escalating cannabinoid doses in healthy dogs

    Randomised blinded placebo-controlled safety study

    Compared CBD-predominant, THC-predominant and combined oils. CBD-predominant oil caused fewer serious adverse effects than the THC-containing comparators.

    Study context and limitations

    Small groups of healthy Beagles; formulation-specific tolerability, not a general dosing recommendation.

    Read the original publication
  • 2025Joint pain

    Full-spectrum cannabis extract for pain in dogs with osteoarthritis

    Randomised double-blind placebo-controlled trial

    The primary pain measure did not show a statistically significant reduction compared with placebo.

    Study context and limitations

    Seventeen dogs and a full-spectrum extract containing THC and other cannabinoids; findings cannot be transferred directly to a different CBD formulation.

    Read the original publication
  • 2020Joint pain

    CBD added to a multimodal analgesic regimen for canine osteoarthritis

    Randomised controlled adjunctive-treatment study

    Reported improvements in owner-rated pain measures when CBD was added to a conventional treatment protocol.

    Study context and limitations

    Twenty-one dogs; concurrent medicines and subjective ratings limit attribution to CBD alone.

    Read the original publication
  • 2019Absorption and tolerability

    CBD-rich hemp: absorption and preliminary safety in dogs and cats

    Pharmacokinetic and preliminary safety study

    Investigated a CBD-rich hemp preparation in healthy dogs and cats, providing species-specific absorption and tolerability information.

    Study context and limitations

    Small healthy-animal study; not evidence of effectiveness for a disease. Do not assume equivalent responses across species.

    Read the original publication
  • 2024Joint pain

    CBD with and without NSAIDs in dogs with mobility problems

    Randomised double-blind placebo-controlled crossover study

    Compared with placebo, owner questionnaires and blinded veterinary assessments showed some improvement while dogs received CBD.

    Study context and limitations

    Gait analysis and activity monitoring did not improve compared with placebo. Increases in a liver enzyme (ALP) were greater when CBD was given with NSAID painkillers.

    Read the original publication
  • 2023Pain after surgery

    CBD- and CBDA-rich hemp extract for pain after cruciate ligament surgery in dogs

    Randomised blinded placebo-controlled trial

    Pain scores, lameness and weight-bearing did not differ from placebo during the four weeks after surgery.

    Study context and limitations

    Forty-one dogs completed the study alongside standard post-operative care. A liver enzyme (ALP) rose in the treated group.

    Read the original publication
  • 2023Epilepsy

    CBD added to antiseizure drugs in dogs with drug-resistant epilepsy

    Randomised double-blind placebo-controlled crossover trial

    At 9 mg/kg a day, dogs had fewer seizures and 24% fewer seizure days than on placebo. A lower dose of 5 mg/kg a day was stopped early because it was unlikely to show a benefit.

    Study context and limitations

    The number of dogs whose seizures fell by at least half did not differ from placebo. Liver enzymes rose, and reduced appetite and vomiting were more common with CBD.

    Read the original publication
  • 2022Epilepsy

    CBD- and CBDA-rich hemp extract for refractory epilepsy in dogs

    Randomised placebo-controlled crossover study

    Seizures fell from an average of 8.0 during placebo to 5.0 during treatment, and 6 of 14 dogs had at least 50% fewer seizures, compared with none on placebo.

    Study context and limitations

    Fourteen dogs, with the extract given alongside existing antiseizure drugs. Some dogs were sleepy or unsteady, and a mild rise in a liver enzyme (ALP) was seen.

    Read the original publication
  • 2024Stress

    Daily THC-free CBD and stress during repeated car travel in dogs

    Blinded placebo-controlled parallel study

    Over six months, dogs given CBD had lower cortisol, less whining and lip licking, and calmer behaviour ratings than the placebo group at one or more time points.

    Study context and limitations

    Nineteen dogs; the effect differed between measures and time points.

    Read the original publication
  • 2025Stress

    CBD treats, alone or with L-tryptophan and α-casozepine, during car travel in dogs

    Blinded placebo-controlled crossover study

    CBD alone at 2 or 4 mg/kg had no significant effect; only the blend with L-tryptophan and α-casozepine reduced the rise in cortisol.

    Study context and limitations

    Fifty-four dogs, each given a single dose before a short car journey. Blood CBD levels varied widely between dogs.

    Read the original publication
  • 2022Skin and itching

    CBD and CBDA oil for dogs with atopic dermatitis

    Randomised double-blind placebo-controlled trial

    Owners rated itching lower in the treated group than in the placebo group after two and four weeks.

    Study context and limitations

    Skin lesion scores did not improve. Thirty-two dogs over four weeks, with existing treatments continued; a liver enzyme (ALP) rose in 4 of 17 treated dogs.

    Read the original publication
  • 2022Tolerability

    Six months of daily THC-free CBD in healthy dogs

    Randomised blinded placebo-controlled safety study

    Daily CBD at 4 mg/kg for six months was well tolerated, with no adverse effects on health or wellbeing compared with placebo.

    Study context and limitations

    Healthy dogs only. A liver enzyme (ALP) rose temporarily in just over half of the CBD group, partly from bone. Not a dosing recommendation.

    Read the original publication
  • 2024Tolerability

    Ninety days of CBD, CBD with CBG, or CBD with CBDA in healthy dogs

    Randomised controlled repeat-dose safety study

    Healthy Beagles given 5 mg/kg of cannabinoids a day for 90 days tolerated all three hemp extracts well.

    Study context and limitations

    Thirty-two healthy Beagles in a study that was not blinded; good tolerability in healthy dogs does not show effectiveness.

    Read the original publication
  • 2021Absorption and medicines

    CBD and phenobarbital given together to healthy dogs

    Randomised pharmacokinetic interaction study

    Giving CBD with the antiseizure drug phenobarbital did not significantly change blood levels of either substance.

    Study context and limitations

    Nine healthy Beagles, not dogs with epilepsy. During longer CBD dosing some dogs had mild digestive signs, and at higher doses some had low blood oxygen or raised liver enzymes (ALP).

    Read the original publication
  • 2021Tolerability

    Escalating cannabinoid doses in healthy cats

    Randomised blinded placebo-controlled safety study

    Compared the tolerability of CBD-predominant, THC-predominant and combined oils in healthy cats.

    Study context and limitations

    Twenty cats across five groups; mild adverse events occurred. Findings depend on the tested oils and do not establish routine doses.

    Read the original publication
  • 2022Tolerability and absorption

    Absorption of a CBD and CBDA hemp paste in cats over one week

    Pharmacokinetic and short-term safety study

    Cats absorbed the cannabinoids from the paste, and a week of twice-daily use caused no behavioural or neurological side effects or clinically relevant changes in blood tests.

    Study context and limitations

    Eight healthy cats for one week, with no placebo group. The paste's manufacturer funded the study.

    Read the original publication
  • 2022Tolerability and absorption

    Escalating single doses of CBD in healthy cats

    Pharmacokinetic and tolerability study

    Single doses of up to 80 mg per kg of body weight were well tolerated; reactions were limited to head shaking, lip smacking and drooling just after dosing.

    Study context and limitations

    Eight research cats and single doses only; this does not show that repeated use is safe or indicate a dose to give.

    Read the original publication
  • 2023Tolerability and absorption

    CBD absorption in cats with and without food

    Randomised crossover pharmacokinetic study

    Cats absorbed about eleven times more CBD when it was given after a meal than on an empty stomach.

    Study context and limitations

    Nine healthy cats given one dose of a purified CBD medicine; effects on health were not studied.

    Read the original publication
  • 2024Longer-term tolerability

    Long-term daily cannabidiol feeding in healthy cats

    Randomised blinded placebo-controlled feeding studies

    Studied CBD absorption and monitored healthy cats during daily supplementation, including a 26-week trial.

    Study context and limitations

    The studied THC-free distillate was generally well tolerated under the trial conditions; this does not establish disease benefits or safety for every cat.

    Read the original publication
  • 2023Mouth and joint pain

    CBD alongside standard treatment for feline gingivostomatitis

    Blinded placebo-controlled trial

    Cats given CBD for 15 days, starting just before tooth extraction, improved significantly more on a disease activity score than cats given placebo. Pain scores also fell further, but that difference was not statistically significant.

    Study context and limitations

    Twenty-two cats; CBD was one part of a treatment that included tooth extraction and pain relief, and the results apply to the tested CBD powder.

    Read the original publication
  • 2025Mouth and joint pain

    CBD and CBDA hemp paste for cats with osteoarthritis pain

    Randomised double-blind placebo-controlled crossover trial

    Pain scores recorded by veterinarians and by owners fell significantly after six weeks of the paste, and blood chemistry did not differ from placebo.

    Study context and limitations

    Only 14 of 26 cats completed the study, mostly because they refused the paste, and some vomited. The paste's manufacturer funded the study.

    Read the original publication
  • 2024Handling and veterinary procedures

    CBD before spaying surgery in cats

    Randomised blinded placebo-controlled trial

    None of the cats given CBD needed extra pain relief during the operation, compared with four of ten given placebo, and they were more sedated before surgery. Pain after surgery was largely similar.

    Study context and limitations

    Twenty-two cats and one dose before surgery; all cats still needed morphine afterwards.

    Read the original publication
  • 2025Handling and veterinary procedures

    CBD oil and anaesthetic requirements in cats

    Before-and-after study without placebo

    A single dose of CBD oil reduced the amount of inhaled anaesthetic cats needed by 11%. Heart and breathing rates were higher at the time of measurement.

    Study context and limitations

    Sixteen healthy cats, one dose given by stomach tube and no placebo group.

    Read the original publication
  • 2025Handling and veterinary procedures

    A single dose of CBD oil and handling in healthy cats

    Single-group study without placebo

    Cats were mildly sedated and resisted handling less two to four hours after CBD, while pain sensitivity, heart rate and breathing did not change.

    Study context and limitations

    Nine healthy cats and a single, relatively high dose; without a placebo group, other influences cannot be ruled out.

    Read the original publication
  • 2022Joint biology

    Cannabinoid receptors in inflamed horse joints

    Tissue study

    In joint lining samples from 25 fetlock joints, both main cannabinoid receptors were present and increased as joint inflammation became more severe.

    Study context and limitations

    Tissue-bank study from the University of Montreal. It identifies possible treatment targets, but no treatment was tested.

    Read the original publication
  • 2023Joint biology

    Cannabinoid receptors in the lining of horse fetlock joints

    Tissue study

    Found cannabinoid and related receptors in the joint lining cells and blood vessels of 14 fetlock joints collected after slaughter.

    Study context and limitations

    Laboratory study by the University of Bologna team, funded by NBF Lanes. No treatment was tested.

    Read the original publication
  • 2024Joint pain

    CBD added to pain treatment for horses with osteoarthritis

    Randomised controlled study

    Twenty horses with mild osteoarthritis received an anti-inflammatory medicine for five days, and half also received CBD oil by mouth for 14 days. The CBD group had lower chronic pain scores.

    Study context and limitations

    A small, short study in which both groups also received phenylbutazone. It does not show the effect of CBD on its own.

    Read the original publication
  • 2024Joint pain

    CBDA, or CBG with CBD, for horses with chronic osteoarthritis

    Comparative study without an untreated group

    Twenty-four horses received either CBDA oil or an oil with CBG and CBD by mouth for 14 days. Pain scores fell in both groups, and no side effects were reported.

    Study context and limitations

    There was no untreated comparison group, and both oils differed from CBD alone. The improvements cannot be attributed to CBD or to Formula Swiss products.

    Read the original publication
  • 2025Pain sensitivity

    Oral CBD and pain sensitivity in healthy horses

    Randomised masked crossover study

    Six horses received CBD oil or a placebo by mouth for three days. CBD raised the heat-sensitivity threshold at some time points but did not change sensitivity to pressure.

    Study context and limitations

    Six healthy horses and an experimental test, so it does not show relief of pain from disease. Heart rate and temperature did not change.

    Read the original publication
  • 2023Behaviour

    CBD for crib-biting in one horse

    Case report

    Describes a 22-year-old mare with long-standing crib-biting and wind-sucking whose behaviour improved during four weeks of CBD.

    Study context and limitations

    A single horse without a comparison group. A case report cannot show that CBD caused the change.

    Read the original publication
  • 2023Behaviour and stress

    Single doses of CBD paste and horse behaviour

    Blinded controlled dose-escalation study

    Horses received a CBD paste or a paste without CBD at three increasing doses. Sedation, facial expressions, heart rate and heart rate variability did not differ between the groups.

    Study context and limitations

    Three to six healthy horses per group, and no side effects were seen. This is part 1 of a linked research programme.

    Read the original publication
  • 2024Behaviour and stress

    Twice-daily CBD paste, horse behaviour and cortisol

    Randomised double-blind controlled study

    Twelve horses received CBD paste or a paste without CBD twice daily for 15 days. Behaviour, heart rate, cortisol and reactions to a new object and trailer loading did not differ between the groups.

    Study context and limitations

    Twelve healthy horses. Linked to the single-dose study from the same programme, rather than an independent repeat.

    Read the original publication
  • 2025Behaviour

    Cannabinoid receptors in a brain area linked to fear and stress

    Tissue study

    Found cannabinoid receptors in the lateral amygdala, a brain area involved in fear, stress and pain, in six horses.

    Study context and limitations

    Laboratory study by the University of Bologna team, funded by NBF Lanes. It did not test whether CBD affects behaviour.

    Read the original publication
  • 2020Wound healing

    CBD in manuka honey on leg wounds in horses

    Preliminary experimental study

    Wounds on the lower legs of six horses were treated daily with 1% CBD in manuka honey, honey alone or saline. Healing did not differ between the treatments.

    Study context and limitations

    Six horses with experimentally created wounds, and the CBD was in a honey carrier rather than an oil. The authors call for further research.

    Read the original publication
  • 2022Skin

    Cannabinoid receptors in healthy horse skin

    Tissue and cell study

    Skin samples and skin cells from 15 healthy horses consistently contained both main cannabinoid receptors.

    Study context and limitations

    Describes normal skin only. It does not show that CBD applied to the skin has an effect.

    Read the original publication
  • 2025Hooves

    Cannabinoid receptors in healthy and laminitic hooves

    Tissue study

    Found cannabinoid receptors in the hoof's lamellar tissue, with higher levels in 12 hooves with laminitis than in six healthy hooves.

    Study context and limitations

    Laboratory study by the University of Bologna team; the paper reports no funding. It suggests a research target, but no laminitis treatment was tested.

    Read the original publication
  • 2025Hooves

    Cannabinoid receptors in immune and connective tissue cells of the hoof

    Tissue study

    Located cannabinoid receptors in immune cells, connective tissue cells, blood vessels and nerve fibres of the hoof in healthy horses and horses with acute or chronic laminitis.

    Study context and limitations

    Laboratory study of 18 hoof samples by the University of Bologna team, funded by NBF Lanes. No treatment was tested.

    Read the original publication
  • 2023Immune function

    Daily CBD for 90 days in senior horses

    Controlled study

    Senior horses received CBD or soy oil by mouth daily for 90 days. CBD lowered some inflammation markers in the blood but did not change the response to vaccination or other health measures.

    Study context and limitations

    Twenty-seven horses. Changes in blood markers do not show a clinical benefit.

    Read the original publication
  • 2025Eyes

    CBD oil and eye pressure in healthy horses

    Before-and-after study without a placebo group

    Eye pressure fell for eight hours after eight healthy horses received one dose of CBD oil by mouth.

    Study context and limitations

    Readings were compared with the same horses the day before, without a placebo. A later controlled study found no clinically relevant change.

    Read the original publication
  • 2026Metabolism

    CBD and metabolism in Connemara ponies

    Randomised controlled study

    Thirteen ponies, seven with equine metabolic syndrome, received CBD or flaxseed oil twice daily for 21 days. CBD did not improve body condition or blood sugar, and insulin responses rose in the CBD group.

    Study context and limitations

    A small study. The authors say the insulin finding may raise concerns for ponies and horses prone to metabolic syndrome.

    Read the original publication
  • 2026Eyes

    Daily CBD, eye pressure and tear production in horses

    Randomised masked crossover study

    Six healthy horses received CBD in sesame oil or a placebo by mouth for three days. Eye pressure and tear production showed no clinically relevant differences.

    Study context and limitations

    Six horses and three days of treatment. The results differ from an earlier study without a placebo group.

    Read the original publication
  • 2021Absorption and tolerability

    Low single doses of CBD in exercising Thoroughbreds

    Randomised crossover study

    Thoroughbreds received three low single doses of CBD in sesame oil by mouth. CBD was well tolerated, with no behavioural, digestive or heart problems, and was still measurable in the blood after 72 hours.

    Study context and limitations

    A small study with mixed effects on inflammation markers. The authors say more research is needed before CBD can be recommended as an anti-inflammatory.

    Read the original publication
  • 2021Absorption and tolerability

    Seven daily doses of a CBD supplement for horses

    Randomised crossover study

    Seven horses received a CBD product made for horses at two daily amounts for seven days. Both were well tolerated, and low levels of THC were also measured in the blood.

    Study context and limitations

    Seven horses and one product that also delivered THC. It did not assess clinical effects.

    Read the original publication
  • 2022Absorption and tolerability

    Six weeks of oral CBD: absorption, joint fluid and safety

    Randomised controlled study

    Twelve horses received CBD twice daily for six weeks, and CBD reached the joint fluid in eight of them. All horses had mildly low calcium and eight had raised liver enzymes, which improved or returned to normal within 10 days of stopping.

    Study context and limitations

    Twelve horses and one oil-based product. Absorption varied widely, and effective doses were not established.

    Read the original publication
  • 2022Absorption and tolerability

    How much CBD senior horses absorb

    Randomised crossover study

    Eight senior horses received a single dose of CBD by mouth or by injection. About 8% of the oral dose reached the bloodstream, and no adverse effects were seen.

    Study context and limitations

    Single doses in eight horses. Low absorption does not establish an effective dose.

    Read the original publication
  • 2022Absorption and tolerability

    Daily CBD pellets for 56 days in Thoroughbreds

    Randomised masked controlled study

    Twenty horses received pellets with or without 150 mg of CBD daily for 56 days. There was no sedation or unsteadiness, and blood tests did not change.

    Study context and limitations

    Healthy horses and one fixed daily amount. The study assessed safety, not benefits.

    Read the original publication
  • 2023Absorption and tolerability

    CBD oil added to feed for mature horses

    Randomised controlled study

    Thirty geldings received a canola-based CBD oil or plain canola oil on their feed for 28 days. The oil was readily eaten, blood chemistry was unaffected and no banned substances were found in the blood.

    Study context and limitations

    Testing showed the product contained far less CBD than its manufacturer's initial analysis indicated, so the horses received much less CBD than planned.

    Read the original publication
  • 2023Absorption and tolerability

    CBD in oil or water-soluble form: absorption in horses

    Randomised crossover study

    Eight horses received CBD by injection and by mouth, in sesame oil or a water-soluble form. About 14% of the oral dose was absorbed with either form, and no adverse reactions were seen.

    Study context and limitations

    Eight horses per trial. The suggested treatment schedules were computer simulations, not tested effects.

    Read the original publication
  • 2024Absorption and tolerability

    Single doses of CBD- and CBDA-rich hemp oil in horses

    Randomised crossover study

    Eight horses received a commercial hemp oil rich in CBD and CBDA at two doses, or no treatment. There were no effects on behaviour, gait, digestion or blood chemistry.

    Study context and limitations

    Single doses only. CBDA reached much higher blood levels than CBD, and the product also contained other cannabinoids.

    Read the original publication
  • 2025Absorption and tolerability

    Six weeks of CBD or CBDA oil: safety and absorption

    Randomised crossover study

    Seven horses received CBD-rich and CBDA-rich hemp oil twice daily for six weeks each. Blood tests and liver biopsies showed no clinically relevant changes, and CBDA reached higher blood levels than CBD.

    Study context and limitations

    Seven healthy horses and full-spectrum extracts. The study assessed safety and absorption, not benefits.

    Read the original publication
  • 2025Absorption and tolerability

    CBD oil or paste, with or without a meal

    Crossover study

    Eight horses received one dose of CBD as an oil or a paste, fed or fasted. Absorption did not differ significantly, although the paste reached its peak level sooner.

    Study context and limitations

    Single doses in eight horses. The study measured absorption only.

    Read the original publication
  • 2025Absorption and tolerability

    One dose of CBD oil in Connemara ponies

    Single-dose absorption study

    Ten ponies received one dose of CBD oil by mouth and tolerated it well. CBD was no longer detectable after 12 days, while a breakdown product remained measurable for 16 days.

    Study context and limitations

    No comparison group. Heart rate was lower and some blood values changed after 24 hours.

    Read the original publication
  • 2025Absorption and tolerability

    CBD compared with CBDA in horses

    Randomised blinded crossover study

    Eight horses received CBD, CBDA or a placebo by mouth. CBDA reached blood levels up to 67 times higher than CBD, and CBD was detectable in urine for up to seven days.

    Study context and limitations

    One pilot horse and seven in the main study; it measured absorption, not effects. First published online in September 2025, journal issue 2026.

    Read the original publication
  • 2025Absorption and tolerability

    How horses absorb and process CBG

    Crossover study

    Eight horses received cannabigerol (CBG) by injection and by mouth, in oil or water-soluble form. About 28% of the oral dose was absorbed, and no adverse effects were seen.

    Study context and limitations

    The first study of CBG in horses. It measured absorption and breakdown, not effects.

    Read the original publication
  • 2023Drug testing

    How long CBD stays in horses: data for doping control

    Single and repeated-dose study

    Measured CBD in blood and urine after single doses and after 15 days of twice-daily CBD paste. After repeated use, CBD left the body slowly, with a half-life of about 161 hours in serum.

    Study context and limitations

    Designed to help testing laboratories interpret results. It does not set official detection times.

    Read the original publication
  • 2024Drug testing

    Hemp straw bedding, CBD oil and urine tests

    Experimental study

    Cannabinoids were found in the urine of horses bedded on hemp straw. The researchers advise against hemp straw bedding before competition unless at least 48 hours pass, and suggest that bedding exposure may be distinguishable from CBD oil use.

    Study context and limitations

    Detection depends on the laboratory method and on each organisation's rules.

    Read the original publication
  • 2026Drug testing

    Contaminated feed and CBD detection in horses

    Experimental study

    Twelve horses ate feed containing small amounts of CBD or CBDA twice daily for three days. Both were detectable in the urine of all horses, but not after more than four days.

    Study context and limitations

    Not designed to set detection times, and routine doping laboratories may be more or less sensitive.

    Read the original publication

Understanding CBD research for animals

How do I choose between the animal formulas?

Start with the product labelled for your animal. The cat, dog and horse formulas have different cannabinoid profiles. Compare the ingredients and laboratory report, and follow the product label.

Where can I read the original research?

Every study below links directly to its original publication, DOI or PubMed record. Formula Swiss-supported Bologna research is distinguished from studies funded or conducted by other organisations.

Can I use an animal oil alongside medicines?

Discuss your animal's health, medicines and any proposed product use with a veterinarian. Research findings do not replace individual veterinary advice or the product's instructions.

About this research library

Research summaries published by Formula Swiss. Original investigators and publications are identified below.

Selected original publications, checked on 12 September 2026. This library is not a systematic review. Study links lead directly to publishers, DOI records or PubMed; short titles describe the subject of each paper. Research is grouped by species and study design to help you interpret the evidence.

Back to the products
Our wider research collaborations

At Formula Swiss, we are more than a producer of high-quality cannabis and hemp products. We also support scientific research into these plants and their applications.

We believe the future of the cannabis and hemp sector should be guided by evidence-based research. Since 2018, we have made it a priority to support and sponsor relevant studies.

Our commitment to research is practical and multi-faceted. We have provided funding and donated cannabis products to research studies worldwide.

We have supported hospitals and doctors in Denmark, Thailand, and Brazil by providing resources for independent cannabinoid research.

Laboratory analysis of CBD oil

A special collaboration with the University of Bologna

Our dedication to expanding knowledge about cannabis and its applications also extends into the veterinary field. We have built a close research collaboration with the Department of Veterinary Medical Sciences at the University of Bologna in Italy.

Professor Roberto Chiocchetti from the University of Bologna

Together with Professor Roberto Chiocchetti and his team of expert researchers, we are exploring cannabidiol (CBD) in animals. The objective is to broaden scientific understanding and use this knowledge to continually improve our CBD pet products.

Our collaboration has included studies involving dogs, cats, and horses. These investigations provide useful insights for product development and for those interested in cannabinoid research for animals.

Read more: Research on cats, dogs, and horses.

How we support research

We support relevant research projects through practical contributions that help researchers and institutions carry out their work.

Funding support

We may provide financial support for selected research projects aligned with our focus areas.

Product donations

We have donated cannabis and hemp products for use in approved research settings.

Research collaboration

We collaborate with researchers, doctors, hospitals, and academic institutions where projects are relevant and properly documented.

All research support is considered carefully and must align with responsible standards, applicable rules, and documented scientific objectives.

Join us in supporting cannabis research

Are you a researcher, academic institution, or industry professional interested in cannabis and hemp research? Do you have a research project that aligns with our mission? We would like to hear from you.

At Formula Swiss, we are open to new partnerships and collaborations that can help advance scientific understanding of cannabis and hemp. We offer various forms of support, from funding to product donations and potential collaboration with our experienced team.

Contact us to discuss how we may be able to support your research project.

Contact us